AI Summary (Part 2)
Opening: Real Consultation Scenario
Clinic Dialogue · Real Scenario
"Doctor, I am 34 years old with a 5-year history of adenomyosis. I need painkillers for every menstrual period. I have been trying to conceive for a year without success, and the local hospital recommended IVF. But I am worried that adenomyosis will affect embryo implantation. I want to know if IVF is feasible for my condition?" — This was the exact words of a patient in my clinic last week. Her ultrasound report showed: heterogeneous echogenicity in the posterior myometrium, scattered small cystic anechoic areas, slightly enlarged uterine volume, CA125 62 U/mL.
Can Patients with Adenomyosis Undergo IVF: Direct Answer
Yes, but it must be based on stratified assessment of the condition. Adenomyosis is not an absolute contraindication for IVF, but the extent and location of the lesions, the degree of impact on the endometrium, as well as the patient's age and ovarian reserve, collectively determine the feasibility and strategy of IVF.
- Mild to moderate adenomyosis (localized lesions, no significant uterine enlargement, basically normal uterine cavity shape): Suitable for IVF. Typically, GnRH-a (gonadotropin-releasing hormone agonist) down-regulation is used for 2-3 months to induce atrophy of ectopic endometrium, reduce uterine volume, and improve the pelvic inflammatory environment before starting the ovulation induction cycle. This protocol has been confirmed by multiple clinical observations to improve embryo implantation rates.
- Severe adenomyosis (diffuse uterine enlargement, uterine cavity deformation, with adenomyoma): Requires individualized assessment. Some patients may need laparoscopic or open surgery for adenomyomectomy or uterine lesion reduction surgery, and then decide whether to enter the IVF cycle based on uterine recovery. Some patients, after strict evaluation, may directly use an ultra-long protocol with down-regulation followed by a trial transfer.
- With endometrioma (chocolate cyst): Ovarian cysts need to be managed simultaneously to prevent them from affecting follicle development or egg retrieval.
Therefore, "whether it is possible" depends on the specific disease classification and the experience of the reproductive center in handling complex cases. There is no uniform yes or no, but a complete evaluation process is required.
Adenomyosis and IVF from a Reproductive Medicine Perspective
The core mechanisms by which adenomyosis affects fertility include: decreased endometrial receptivity, local inflammatory response leading to embryo toxicity, abnormal uterine peristalsis interfering with embryo positioning, and possible pelvic adhesions affecting tubal function. For IVF, the most direct challenges are decreased embryo implantation rate and increased early miscarriage rate.
GnRH-a down-regulation has become the basic protocol for IVF with adenomyosis because it suppresses the pituitary-ovarian axis, reduces endogenous estrogen levels, and causes temporary atrophy of ectopic endometrium, thereby improving the uterine environment. However, it should be noted that down-regulation is not equally effective for all adenomyosis patients. The more extensive the lesions and the heavier the fibrosis, the poorer the drug response.
Additionally, ovarian reserve function in adenomyosis patients needs independent assessment. Some adenomyosis patients also have ovarian endometriomas or have undergone surgery for adenomyosis, which may affect ovarian reserve. Therefore, AMH and antral follicle count (AFC) are essential tests before IVF.
Differences in IVF Strategies for Adenomyosis Patients by Age Group
Age is an independent factor affecting IVF outcomes, and this rule also applies to adenomyosis patients. However, the presence of adenomyosis amplifies the adverse effects of age, so strategies need to be more refined.
| Age Group | Common Characteristics | Recommended IVF Strategy |
|---|---|---|
| ≤ 35 years | Relatively adequate ovarian reserve, usually shorter disease duration | Standard down-regulation protocol (2-3 GnRH-a injections) followed by ovulation induction; if lesions are localized, a mild stimulation protocol may be considered |
| 35 – 40 years | Ovarian reserve begins to decline, adenomyosis may have progressed | Emphasize quality of down-regulation, use individualized ovulation induction protocols (e.g., PPOS or antagonist protocol combined with down-regulation); recommend completing embryo freezing as early as possible for elective frozen embryo transfer |
| ＞ 40 years | Significantly decreased ovarian reserve, increased miscarriage risk | Need to balance down-regulation and oocyte yield; some patients may consider embryo accumulation strategies; also recommend genetic counseling and PGT-A (preimplantation genetic testing for aneuploidy) |
Note: In older adenomyosis patients, deep pituitary suppression during down-regulation may cause difficulty in initiating ovulation induction, requiring the reproductive doctor to dynamically adjust the protocol based on FSH and LH levels.
Differences in Management of Adenomyosis Among Reproductive Centers
Different reproductive centers have varying experience in managing infertility related to adenomyosis, mainly reflected in the following aspects:
- Choice of down-regulation protocol: Some centers routinely use 3 GnRH-a injections (ultra-long protocol), while others flexibly adjust the number of injections (1-3) based on uterine volume and CA125 levels.
- Transfer strategy: For adenomyosis patients, preferences differ between fresh embryo transfer and freeze-all followed by elective frozen embryo transfer. Current evidence suggests that frozen embryo transfer may be beneficial for adequate preparation of the uterine environment.
- Endometrial receptivity assessment: Some centers routinely perform endometrial receptivity array (ERA) or ultrasound assessment of endometrial blood flow to determine the optimal transfer window. This test may be more valuable for adenomyosis patients.
- Multidisciplinary collaboration: Some centers have dedicated MDT teams for endometrial diseases, involving reproductive doctors, ultrasound doctors, and hysteroscopy doctors in formulating plans.
Therefore, when choosing a reproductive center, adenomyosis patients can focus on the center's experience in managing endometrial-related diseases and whether there are targeted down-regulation and transfer protocols.
Easily Overlooked Details in IVF with Adenomyosis
① Endometrial monitoring after down-regulation: After GnRH-a treatment, endometrial growth may be delayed or thin in some patients. Continuous ultrasound monitoring should start from day 10-12 after stopping the medication, and low-dose estrogen supplementation should be used if necessary to avoid excessively thin endometrium affecting transfer.
② Individualized transfer window: The endometrial receptivity window may be shifted in adenomyosis patients. For those with repeated implantation failure, ERA testing is recommended to determine the most appropriate transfer time.
③ Intensity of luteal support: Luteal support after transfer in adenomyosis patients requires more adequate progesterone supplementation. Intramuscular progesterone injection or vaginal progesterone gel combined with oral progesterone is a common protocol, but the dose should be adjusted based on serum progesterone levels.
④ Pain management: Adenomyosis patients may experience abdominal pain due to uterine contractions during ovulation induction and after transfer. Mild pain can be observed, while moderate to severe pain requires timely communication with the doctor, and if necessary, the use of embryo-safe analgesics (e.g., acetaminophen).
⑤ Dynamic assessment of uterine volume: Uterine volume decreases after down-regulation but may increase again after stopping medication. Ultrasound should be performed again before transfer to reassess uterine size and endometrial condition to ensure optimal status.
Actual IVF Process for Patients with Adenomyosis
From initial consultation to transfer, the IVF process for adenomyosis patients includes two additional key steps compared to routine cycles: assessment and down-regulation. The following is a general process (specifics depend on the treating center):
- Initial consultation and assessment: Detailed history taking by the reproductive doctor (degree of dysmenorrhea, duration of trying to conceive, previous surgical history), gynecological examination, and ordering of tests.
- Systematic examinations: Including ultrasound (assess uterine size, myometrial echogenicity, endometrial morphology), CA125, AMH, AFC, thyroid function, semen analysis, etc. Pelvic MRI (for more precise lesion extent) and hysteroscopy (to assess uterine cavity shape) may be added if necessary.
- Disease grading and protocol formulation: Based on comprehensive test results, determine the severity of adenomyosis and select a down-regulation protocol (1-3 GnRH-a injections, one every 28 days).
- Down-regulation cycle: After completing the prescribed number of GnRH-a injections, confirm via ultrasound that uterine volume has decreased, endometrial thickness is adequate, and ovaries are in a quiescent state, then initiate ovulation induction.
- Ovulation induction and egg retrieval: Choose appropriate ovulation induction medications and doses based on ovarian response, administer HCG or GnRH-a trigger at the right time, and perform egg retrieval 36 hours later.
- Embryo culture and freezing: After egg retrieval, perform in vitro fertilization and embryo culture. Adenomyosis patients often adopt a freeze-all strategy, transferring embryos only after the uterine environment is adequately prepared.
- Endometrial preparation and transfer: Prepare the endometrium using an artificial cycle or natural cycle, and transfer 1-2 embryos at the optimal time. Continue luteal support after transfer.
- Post-transfer management: Check blood HCG on day 12-14 after transfer to confirm pregnancy. If pregnant, continue luteal support until 10-12 weeks of gestation and closely monitor uterine changes.
For patients returning from overseas for IVF, it is recommended to reserve at least 3-4 months (including the down-regulation cycle), prepare documents such as passport, marriage certificate, and birth notarization in advance, and confirm the validity of test reports (some tests need to be within 3 months).
Key Examination Indicators and Their Interpretation
| Examination Item | Purpose | General Interpretation Reference |
|---|---|---|
| Gynecological Ultrasound | Assess uterine size, myometrial echogenicity, endometrial thickness, presence of adenomyoma | Diffuse myometrial thickening, small cystic anechoic areas suggest adenomyosis; uterine volume > 8 weeks gestational size often indicates severe disease |
| CA125 | Auxiliary assessment of adenomyosis activity | Mild elevation (35-100 U/mL) common in adenomyosis; levels > 200 U/mL may indicate severe disease or co-existing endometriosis |
| AMH | Assess ovarian reserve | Levels < 1.0 ng/mL suggest diminished ovarian reserve; levels > 3.0 ng/mL indicate good reserve |
| Antral Follicle Count (AFC) | Assess ovarian responsiveness | Total AFC < 5-7 suggests poor response; > 10-15 indicates normal response |
| Pelvic MRI | Precisely show lesion extent, depth, and relationship with uterine cavity | Helps differentiate adenomyosis from adenomyoma; assesses depth of myometrial invasion |
| Hysteroscopy | Direct visualization of uterine cavity shape and endometrial status | Can identify intrauterine adhesions, polyps, or cavity deformities caused by adenomyosis |
| Semen Analysis | Rule out male factor | Assess sperm concentration, motility, and morphology |
The above test results need to be comprehensively interpreted by a reproductive doctor; an abnormality in a single indicator cannot directly determine IVF feasibility.
Frequently Asked Questions
The success rate is most affected by age, lesion severity, and ovarian reserve. In young (≤35 years) patients with mild to moderate adenomyosis, after adequate down-regulation, the ongoing pregnancy rate per single frozen embryo transfer is about 40%-55% (data from some domestic centers). The success rate significantly decreases in patients with severe adenomyosis or advanced age. It is not recommended to measure with a single number but to obtain an expected range through individualized assessment.
Not necessarily. Surgery is usually recommended only in the following situations: ① Adenomyoma diameter > 4 cm and compressing the uterine cavity; ② Significant diffuse uterine enlargement (> 10 weeks gestational size) with poor response to medical down-regulation; ③ Co-existing endometrioma requiring surgical management. The purpose of surgery is to improve the uterine cavity environment and relieve pain, but surgery itself may damage the myometrium, and uterine recovery (usually 6-12 months) is needed before IVF.
Generally 2-3 months. One GnRH-a injection is given every 28 days. Most patients require 2-3 injections for significant improvement in uterine volume and symptoms. Patients with extensive lesions or severe symptoms may need 4 injections. After stopping the medication, wait for menstruation to return or directly initiate ovulation induction (depending on the protocol).
No. Normal daily activities are fine; avoid strenuous exercise and heavy physical labor. Uterine contractions may be more noticeable in adenomyosis patients after transfer, but bed rest does not reduce contractions. It is recommended to maintain emotional stability and avoid constipation and increased abdominal pressure.
Adenomyosis is a polygenic disease with a familial aggregation tendency, but it is not directly inherited. There is currently no evidence that IVF increases the risk of the disease in offspring. The probability of female offspring developing the disease in the future is slightly higher than the general population, but there are no effective prenatal preventive measures.
⚠️ Risk Reminder
Patients with adenomyosis undergoing IVF need to fully understand the following risks:
- Increased miscarriage risk: The early miscarriage rate in adenomyosis patients is about 1.5-2 times that of routine IVF. Even after successful transfer, enhanced monitoring in early pregnancy is required.
- Risk of preterm birth and placental abnormalities: Abnormal uterine environment may increase the risk of late miscarriage, preterm birth, placenta previa, or placenta accreta. Pregnancy should be managed as high-risk, with increased frequency of prenatal check-ups.
- Risk of lesion aggravation: High estrogen levels during pregnancy may temporarily enlarge adenomyosis lesions in some patients, causing pain or bleeding. In most cases, this resolves after delivery, but communication with the obstetrician in advance is necessary.
- Risk of multiple pregnancy: Transferring multiple embryos in adenomyosis patients increases uterine burden. Single embryo transfer is generally recommended to reduce pregnancy complications.
- Ovarian Hyperstimulation Syndrome (OHSS): If combined with polycystic ovary-like changes or high AMH, vigilance for OHSS during ovulation induction is needed.
The above risks are not inevitable but require full informed consent before starting IVF and joint development of a contingency plan with the reproductive doctor.
Author Identity Reproductive Doctor | Knowledge Base ID REP-END-2025-037
This article is compiled based on clinical consensus in assisted reproductive medicine and mainstream reproductive center practices in China in 2025. The content is for popular science reference only and does not constitute medical advice. Please follow the opinion of your treating physician for specific diagnosis and treatment plans.
Comments (0)